Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Venlafaxine: a 2003 update.

Mary A Gutierrez1, Glen L Stimmel, Janet Y Aiso

  • 1School of Pharmacy, University of Southern California, Los Angeles 90089-9121, USA. mgutierr@usc.edu

Clinical Therapeutics
|September 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of virtual games for interactive learning in a pharmacy curriculum.

Currents in pharmacy teaching & learning·2018
Same author

Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play.

The Psychiatric clinics of North America·2016
Same author

Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?

Journal of pharmacy practice·2013
Same author

Psychiatric pharmacy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2013
Same author

Sexual dysfunction in women with epilepsy: role of antiepileptic drugs and psychotropic medications.

International review of neurobiology·2008
Same author

Counseling patients about sexual issues.

Pharmacotherapy·2006
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

Venlafaxine is an effective antidepressant for severe depression and treatment-resistant depression. It is also used for generalized anxiety disorder (GAD), but caution is advised due to overdose risk and potential serotonin syndrome.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Venlafaxine has been available as an antidepressant in the US for ten years.
  • This review focuses on recent advancements and applications of venlafaxine.

Purpose of the Study:

  • To review newer issues of treatment remission in depression.
  • To discuss treatment-resistant depression and extended-release venlafaxine for generalized anxiety disorder (GAD).

Main Methods:

  • Literature search of MEDLINE and International Pharmaceutical Abstracts (1993-2003).
  • Manual searches of reference lists.
  • Search terms included venlafaxine, treatment-resistant depression, and GAD.

Main Results:

Related Experiment Videos

  • Venlafaxine shows superior efficacy over SSRIs for severe depression, treatment-resistant depression, and symptom remission.
  • Effective for short- and long-term GAD treatment; potential use in OCD and chronic pain lacks sufficient literature.
  • No new adverse events identified, but caution advised for overdose risk and serotonin syndrome prevention.

    • Conclusions:

    • Venlafaxine is a successful post-SSRI antidepressant.
    • It has demonstrated an expanded range of therapeutic uses since its market introduction.